<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362410</url>
  </required_header>
  <id_info>
    <org_study_id>D5180C00020</org_study_id>
    <nct_id>NCT04362410</nct_id>
  </id_info>
  <brief_title>Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects</brief_title>
  <acronym>DIRECTION-CK</acronym>
  <official_title>A Phase 1, Single Centre, Double-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Tezepelumab After Single-Dose Subcutaneous Administration in Healthy Chinese Subjects (DIRECTION-CK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, Single Centre, Double-blind, Randomized, Placebo-controlled Parallel-group
      Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of
      Tezepelumab after Single-Dose Subcutaneous Administration in Healthy Chinese Subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, single centre, randomized, double-blind, placebo-controlled, single dose,
      parallel group study in healthy Chinese male or female subjects. 48 healthy subjects will be
      randomly assigned to one of the three treatment cohorts (i.e. 1:1:1 to Low dose, Medium dose
      and High dose) to receive a single dose of tezepelumab or placebo in a 3:1 ratio. Each
      subject will only participate in one cohort. Dose level is unblinded and treatment
      (tezepelumab or placebo) will be double-blinded within each treatment cohort. Following a
      screening period of a maximum of 28 days, subjects will stay at the study facility for two
      nights starting from the day before dosing (Day -1) to Day 2. Subjects will receive a single
      dose of tezepelumab or placebo subcutaneously on Day 1 and safety monitoring and serial
      collection of blood samples for PK evaluation will be followed throughout the study period.
      The follow up period after the dosing will be 112 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">November 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>48 healthy subjects will be randomly assigned to one of the three treatment cohorts (i.e. 1:1:1 to Low dose, Medium dose and High dose). 16 subjects will participate in each treatment cohort. Within each cohort, subjects will be randomized in a 3:1 ratio to receive a single dose of tezepelumab or placebo. Each subject will only participate in one cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf (Area under the serum concentration versus time curve from time zero to Infinity)</measure>
    <time_frame>Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.</time_frame>
    <description>To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (Area under the serum concentration versus time curve from time zero to the last quantifiable concentration)</measure>
    <time_frame>Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.</time_frame>
    <description>To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum serum concentration)</measure>
    <time_frame>Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.</time_frame>
    <description>To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (time to Cmax)</measure>
    <time_frame>Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.</time_frame>
    <description>To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (terminal serum half-life)</measure>
    <time_frame>Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.</time_frame>
    <description>To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (apparent serum clearance)</measure>
    <time_frame>Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.</time_frame>
    <description>To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F (apparent volume of distribution)</measure>
    <time_frame>Blood samples will be collected from Day 1 (3 hour prior to administration of IP) and on Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 15, Day 22, Day 29, Day 43, Day 57, Day 85 and Day 113.</time_frame>
    <description>To investigate the pharmacokinetics of single subcutaneous dose of tezepelumab in healthy Chinese subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity anti-drug antibodies</measure>
    <time_frame>Blood samples will be collected on Day 1 (3 hour prior to administration of IP) and on Day 29, Day 113.</time_frame>
    <description>Incidence of anti-drug antibodies following single dose of tezepelumab</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Tezepelumab: Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tezepelumab: Tezepelumab single dose subcutaneously injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tezepelumab: Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tezepelumab: Tezepelumab single dose subcutaneously injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tezepelumab: High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tezepelumab: Tezepelumab single dose subcutaneously injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single dose subcutaneously injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental: Tezepelumab</intervention_name>
    <description>Tezepelumab single dose subcutaneously injection.</description>
    <arm_group_label>Tezepelumab: High dose</arm_group_label>
    <arm_group_label>Tezepelumab: Low dose</arm_group_label>
    <arm_group_label>Tezepelumab: Medium dose</arm_group_label>
    <other_name>Tezepelumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo single dose subcutaneously injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female healthy Chinese subjects

          -  Age 18 to 45

          -  Body weight â‰¥ 40 kg

          -  Body mass index (BMI) between 19-24 kg/m2

        Exclusion Criteria:

          -  History or evidence of a clinically significant disorder

          -  History of cancer

          -  Smokers of &gt; 5 cigarettes/day

          -  Receipt of any marketed or investigational biologic within 4 months or 5
             half-lives/non-biologic agent within 30 days or 5 half-lives prior to randomization

          -  History of chronic alcohol or drug abuse

          -  Hepatitis B, C or HIV

          -  Pregnant or breastfeeding

          -  History of anaphylaxis following any biologic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinfang Hu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Tezepelumab</keyword>
  <keyword>Healthy Chinese Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

